The current and future disease burden of chronic hepatitis C virus infection in Egypt

Arab Journal of Gastroenterology

Volumn 15, Issue 2, 2014, Pages 45-52

  Waked, Imam ^a   Doss, Waheed ^b   El Sayed, Manal Hamdy ^c   Estes, Chris ^d   Razavi, Homie ^d   Shiha, Gamal ^e   Yosry, Ayman ^b   Esmat, Gamal ^b  

^a National Liver Institute   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d Center for Disease Analysis   (United States)

^e MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; EGYPT; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INFECTION RATE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; BIOLOGICAL MODEL; FORECASTING; HEPATITIS C, CHRONIC; PREVALENCE;

EGYPT; FORECASTING; HEPATITIS C, CHRONIC; HUMANS; MODELS, BIOLOGICAL; PREVALENCE;

EID: 84905232893     PISSN: 16871979     EISSN: 20902387     Source Type: Journal    
DOI: 10.1016/j.ajg.2014.04.003     Document Type: Review

References (80)

1. Mohamed M.K., Bakr I., El-Hoseiny M., Arafa N., Hassan A., Ismail S., et al. HCV-related morbidity in a rural community of Egypt. J Med Virol 2006, 78:1185-1189.
2. Mohamoud Y.A., Mumtaz G.R., Riome S., Miller D., Abu-Raddad L.J. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013, 13:288. 10.1186/1471-2334-13-288.
3. Arafa N., El Hoseiny M., Rekacewicz C., Bakr I., El-Kafrawy S., El Daly M., et al. Changing pattern of hepatitis C virus spread in rural areas of Egypt. J Hepatol 2005, 43:418-424.
4. Eassa S., Eissa M., Sharaf S.M., Ibrahim M.H., Hassanein O.M. Prevalence of hepatitis C virus infection and evaluation of a health education program in El-Ghar village in Zagazig, Egypt. J Egypt Public Health Assoc 2007, 82:379-404.
5. Strickland G.T., Elhefni H., Salman T., Waked I., Abdel-Hamid M., Mikhail N.N., et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg 2002, 67:436-442.
6. Razavi H., Elkhoury A.C., Elbasha E., Estes C., Pasini K., Poynard T., et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013, 57:2164-2170.
7. Davis G.L., Alter M.J., El-Serag H., Poynard T., Jennings L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
8. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
9. Sievert W., Altraif I., Razavi H.A., Abdo A., Ahmed E.A., Alomair A., et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(Suppl. 2):61-80.
10. Pybus O.G., Drummond A.J., Nakano T., Robertson B.H., Rambaut A. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 2003, 20:381-387.
11. Paez Jimenez A., Sharaf Eldin N., Rimlinger F., El-Daly M., El-Hariri H., El-Hoseiny M., et al. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 2010, 59:1554-1560.
12. Frank C., Mohamed M.K., Strickland G.T., Lavanchy D., Arthur R.R., Magder L.S., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355(9207):887-891.
13. El-Zanaty F, Way A. Egypt Demographic and Health Survey, 2008 Cairo, Egypt: Ministry of Health and Population, 2009; 2009. Demographic and Health Survey (EDHS).
14. Razavi H., Waked I., Sarrazin C., Myers R.P., Idilman R., Calinas F., et al. The present and future disease Burden of hepatitis C virus with today's treatment paradigm. J Viral Hepat 2014, 21(Suppl. 1):34-59.
15. Central Agency for Public Mobilization and Statistics, CAPMAS. Estimates of Midyear Population by Age Groups (2006-2012). Nov 21 2013 [cited:March 09 2014] Available from: URL: . http://www.capmas.gov.eg/pdf/Electronic%20Static%20Book2013/english/population/untitled1/pop.aspx.
16. Abdel-Hamid M., El-Daly M., Molnegren V., El-Kafrawy S., Abdel-Latif S., Esmat G., et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007, 88:1526-1531.
17. El-Zayadi A., Simmonds P., Dabbous H., Selim O. Hepatitis C virus genotypes among HCV-chronic liver disease patients in Egypt: a leading trial. J Egypt Public Health Assoc 1994, 69:327-334.
18. Ray S.C., Arthur R.R., Carella A., Bukh J., Thomas D.L. Genetic epidemiology of hepatitis. J Infect Dis 2000, 182:698-707.
19. Doss W, Mohamed MK, Esmat G, El Sayed M, Fontanet A, Cooper S, et al. Egyptian national control strategy for viral hepatitis 2008-2012. Arab Republic of Egypt, Ministry of Health and Population, National Committee for the Control of Viral Hepatitis; 2008 Apr. Available at: (accessed March 10, 2014). http://www.hepnile.org/images/stories/doc/NSP_10_April_2008_final2.pdf.
20. Mohamed M.K., Abdel-Hamid M., Mikhail N.N., Abdel-Aziz F., Medhat A., Magder L.S., et al. Intrafamilial transmission of hepatitis C in Egypt. Hepatology 2005, 42:683-687.
21. Mostafa A., Taylor S.M., El-Daly M., El Hoseiny M., Bakr I., Arafa N., et al. Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections. Liver Int 2010, 30:560-566.
22. Breban R., Doss W., Esmat G., ElSayed M., Hellard M., Ayscue P., et al. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat 2012, 20:294-296.
23. Miller F.D., Abu-Raddad L.J. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010, 107:14757-14762.
24. El-Raziky M.S., El-Hawary M., El-Koofy N., Okasha S., Kotb M., Salama K., et al. Hepatitis C virus infection in Egyptian children: single centre experience. J Viral Hepat 2004, 11:471-476.
25. Saleh D.A., Shebl F.M., El-Kamary S.S., Magder L.S., Allam A., Abdel-Hamid M., et al. Incidence and risk factors for community-acquired hepatitis C infection from birth to 5years of age in rural Egyptian children. Trans R Soc Trop Med Hyg 2010, 104:357-363.
26. Ryder S.D., Irving W.L., Jones D.A., Neal K.R., Underwood J.C. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004, 53:451-455. Trent Hepatitis C Study Group.
27. Varghese R., Al-Khaldi J., Asker H., Fadili A.A., Al Ali J., Hassan F.A. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology 2009, 56:218-222.
28. Irshad M., Ansari M.A., Singh A., Nag P., Raghvendra L., Singh S., et al. HCV-genotypes: a review on their origin, global status, assay system, pathogenicity and response to treatment. Hepatogastroenterology 2010, 57:1529-1538.
29. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
30. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., et al. HCV RESPOND-2 investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
31. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
32. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
33. Sherman K.E., Flamm S.L., Afdhal N.H., Nelson D.R., Sulkowski M.S., Everson G.T., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011, 365:1014-1024.
34. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
35. El Raziky M., Fathalah W.F., El-Akel W.A., Salama A., Esmat G., Mabrouk M., et al. The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: a single centre Egyptian study. Hepat Mon 2013, 13:e10069.
36. Esmat G., El Kassas M., Hassany M., Gamil M., El Raziky M. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver Int 2014, 34(Suppl. 1):24-28.
37. Taha A.A., El-Ray A., El-Ghannam M., Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010, 24:597-602.
38. Health Insurance Organization Higher Committee for Liver Disease: data on file; 2013. Unpublished.
39. Gad R.R., Males S., El Makhzangy H., Shouman S., Hasan A., Attala M., et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008, 28:1112-1119.
40. El Makhzangy H., Esmat G., Said M., Elraziky M., Shouman S., Refai R., et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009, 81:1576-1583.
41. Moucari R., Ripault M.P., Martinot-Peignoux M., Voitot H., Cardoso A.C., Stern C., et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009, 58:1662-1669.
42. Roulot D., Bourcier V., Grando V., Deny P., Baazia Y., Fontaine H., et al. Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007, 14:460-467.
43. Asselah T., De Muynck S., Broët P., Masliah-Planchon J., Blanluet M., Bièche I., et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012, 56:527-532.
44. De Nicola S., Aghemo A., Rumi M.G., Galmozzi E., Valenti L., Soffredini R., et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012, 55:336-342.
45. Stättermayer A.F., Strassl R., Maieron A., Rutter K., Stauber R., Strasser M., et al. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 2014, 39:104-111.
46. Antaki N., Bibert S., Kebbewar K., Asaad F., Baroudi O., Alideeb S., et al. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J Viral Hepat 2013, 20:59-64.
47. El Awady M.K., Bader N.G., Tabll A., El Hosary Y., Abdel Aziz A.O., El Khayat H., et al. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World J Gastroenterol 2013, 19:290-298.
48. Ragheb M.M., Nemr N.A., Kishk R.M., Mandour M.F., Abdou M.M., Matsuura K., et al. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int 2013, 16. [Epub ahead of print]. 10.1111/liv.12321.
49. Khattab M., Emad M., Abdelaleem A., Eslam M., Atef R., Shaker Y., et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010, 30:447-454.
50. Marcellin P., Cheinquer H., Curescu M., Dusheiko G.M., Ferenci P., Horban A., et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012, 56:2039-2050.
51. Ferenci P., Laferl H., Scherzer T.M., Gschwantler M., Maieron A., Brunner H., et al. Austrian Hepatitis Study Group. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008, 135:451-458.
52. El Khayat H.R., Fouad Y.M., El Amin H., Rizk A. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. Trop Gastroenterol 2012, 33:112-117.
53. Khattab M.A., Ferenci P., Hadziyannis S.J., Colombo M., Manns M.P., Almasio P.L., et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011, 54:1250-1262.
54. Rossignol J.F., Kabil S.M., El-Gohary Y., Elfert A., Keeffe E.B. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008, 28:574-580.
55. Rossignol J.F., Elfert A., El-Gohary Y., Keeffe E.B. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009, 136:856-862.
56. Sabry A, El-Shimi E, El-Haddad O, El-Saeed H, Taha H, Waked I. Failure of nitazoxanide to improve response of hepatitis C patients to pegylated interferon and ribavirin therapy. EASL/AASLD special conference: Therapy of Hepatitis C: Clinical Application and Drug Development, Prague, Czech Republic, September 2012 (Abstract).
57. Shehab H.M., Elbaz T.M., Deraz D.M. Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial. Liver Int 2014, 34:259-265.
58. Abu-Mouch S., Fireman Z., Jarchovsky J., Zeina A.R., Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol 2011, 17:5184-5190.
59. El-Deeb E. MD thesis, National Liver Institute; 2013.
60. Asselah T., Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012, 32(Suppl. 1):88-102.
61. Palanisamy N., Danielsson A., Kokkula C., Yin H., Bondeson K., Wesslén L., et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 2013, 99:12-17.
62. Schneider M.D., Sarrazin C. Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?. Antiviral Res 2014 Feb 25, [doi:pii: S0166-3542(14)00054-0].
63. Benhamou Y., Moussalli J., Ratziu V., Lebray P., De Backer K., De Meyer S., et al. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis 2013, 208:1000-1007.
64. Ruane P.J., Ain D., Riad J., Meshrekey R.G., Stryker R., Wolfe P.R., et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian ancestry. Hepatology 2013, 58:737A. [Abstract #1090].
65. Everson G., Cooper C., Hézode C., Shiffman M.L., Yoshida E., Beltran-Jaramillo T., et al. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int 2014, [Epub ahead of print]. 10.1111/liv.12471.
66. Hézode C., Hirschfield G.M., Ghesquiere W., Sievert W., Rodriguez-Torres M., Shafran S., et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results. AASLD 2012. Hepatology 2012, 56:117A. [Abstract].
67. Moreno C., Hezode C., Marcellin P., Bourgeois S., Francque S., Samuel D., et al. Simeprevir with peginterferon/ribavirin for treatment of chronic HCV genotype 4 infection in treatment-naïve or-experienced patients: interim results of a phase III trial HEPDART 2013. Global Antivir J 2013, 9(Suppl. 2):62. [Abstract #60].
68. Schinazi R., Halfon P., Marcellin P., Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014, 34(Suppl. 1):69-78.
69. Lawitz E., Poordad F.F., Pang P.S., Hyland R.H., Ding X., Mo H., et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014, 383:515-523.
70. Gane E.J., Stedman C.A., Hyland R.H., Ding X., Svarovskaia E., Subramanian G.M., et al. Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection. Gastroenterology 2014, 146:736-743.
71. Gilead press release: . http://www.gilead.com/news/press-releases/2014/2/gilead-files-for-us-approval-of-ledipasvirsofosbuvir-fixeddose-combination-tablet-for-genotype-1-hepatitis-c.
72. Jacobson IM, Ghalib R, Rodriguez-Torres M, Younossi Z, Corregidor A, Sulkowski M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study. In: Presented at the 64th Annual Meeting of the AASLD; November 1-5, 2013; Washington, DC (Abstract #LB-3).
73. Kowdley K.V., Lawitz E., Poordad F., Cohen D.E., Nelson D.R., Zeuzem S., et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014, 370:222-232.
74. ABBVIE press release: ABBVIE completes largest phase III program of an all-oral, interferon free therapy for the treatment of hepatitis C genotype 1. Accessed March 9, 2014. http://abbvie.mediaroom.com/2014-01-31-AbbVie-Completes-Largest-Phase-III-Program-of-an-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Hepatitis-C-Genotype-1.
75. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Reddy K.R., Hassanein T., Jacobson I., et al. AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221.
76. Everson G.T., Sims K.D., Rodriguez-Torres M., Hézode C., Lawitz E., Bourlière M., et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014, 146:420-429.
77. Casey L., Lee W. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol 2013, 29:243-249.
78. Janssen H.L., Reesink H., Lawitz E., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.
79. Global Health Observatory of the World Health Organization: downloaded from: . http://apps.who.int/gho/athena/data/download.xsl?format=xml%26target=GHO/LIFE_0000000029,LIFE_0000000030,LIFE_0000000031,LIFE_0000000032,LIFE_0000000033,LIFE_0000000034,LIFE_0000000035%26profile=excel%26filter=COUNTRY:EGY;YEAR:2011.
80. Aleman S., Rahbin N., Weiland O., Davidsdottir L., Hedenstierna M., Rose N., et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013, 57:230-236.